The complaint filed against the New York-based firm claims that Zoetis misled the market about the true status of its veterinary pharmaceutical portfolio throughout the specified class period. Plaintiffs allege that the company failed to disclose significant challenges affecting key products, causing potential financial harm to shareholders.
Zoetis Faces Securities Class Action Over Alleged Misleading Statements
Investors who purchased Zoetis Inc. stock between January 14, 2025, and May 6, 2026, face a July 27 deadline to join a class action lawsuit. The litigation alleges that the company violated federal securities laws by issuing false statements regarding the performance of its core product lines, including Librela, Apoquel, and Cytopoint.
The DJS Law Group is currently organizing the litigation and seeking potential lead plaintiffs to represent the class. Shareholders interested in participating or inquiring about their legal rights are encouraged to contact the firm directly before the late-July cutoff. Participation as a lead plaintiff is optional, and individual investors may still be eligible for recovery without assuming a formal leadership role in the proceedings.
Comments (0)
No comments yet. Be the first!